<DOC>
	<DOCNO>NCT01955837</DOCNO>
	<brief_summary>To compare effect TAS-102 placebo patient metastatic colorectal cancer refractory intolerable standard chemotherapy .</brief_summary>
	<brief_title>Study TAS-102 Patients With Metastatic Colorectal Cancer Asia</brief_title>
	<detailed_description>This multinational , double-blind , two-arm , parallel , randomized Phase 3 comparison study evaluate efficacy safety TAS-102 versus placebo patient refractory metastatic colorectal cancer . Patients randomly assign ( 2:1 ) TAS-102 ( experimental arm ) placebo ( control arm ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Has provide write informed consent Has adenocarcinoma colon rectum Has fail least 2 prior regimen standard chemotherapy metastatic colorectal cancer ECOG performance status 0 1 Is able take medication orally Has adequate organ function ( bone marrow , kidney liver ) Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>